Chlamydia

UT Health San Antonio to lead $11 million, NIH-funded study of a first-ever oral chlamydia vaccine

Retrieved on: 
Venerdì, Maggio 10, 2024
Infection, Vaccination, University, Pelvic inflammatory disease, Bangladesh Technical Education Board, Molecular genetics, Rutgers University, Zhong, Mouse, Chlamydia, Food, Tissue, Infertility, Texas Biomedical Research Institute, University of Texas System, Doctor of Philosophy, Research, Vaccine, IND, NIAID, Disease, GI, Investigational New Drug, Gastrointestinal tract, DVM, Microbiology, MPH, Immunology, Vertically transmitted infection, HPV, Workforce, Hepatitis B, SAN, Hepatitis A

SAN ANTONIO, May 9, 2024 /PRNewswire-PRWeb/ -- A research team led by The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been awarded approximately $11 million over five years by the National Institutes of Health to study a first-ever chlamydia vaccine.

Key Points: 
  • The University of Texas Health Science Center at San Antonio (UT Health San Antonio) will direct a team of researchers to investigate a novel oral vaccine for chlamydia, the most reported sexually transmitted disease, with funding from the National Institutes of Health.
  • SAN ANTONIO, May 9, 2024 /PRNewswire-PRWeb/ -- A research team led by The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been awarded approximately $11 million over five years by the National Institutes of Health to study a first-ever chlamydia vaccine.
  • The UT Health San Antonio-led study of a novel oral vaccine that could protect against chlamydia infection is being funded through a cooperative agreements research project grant, known as a U01 grant.
  • Back in 2022, UT Health San Antonio was granted an exclusive global license to allow Ohio biopharmaceutical company Blue Water Vaccines Inc. to develop Zhong's findings into an oral vaccine for chlamydia.

Testmate Health Raises $6M In Seed Funding For First Low-Cost, At-Home STI Diagnostic Test

Retrieved on: 
Mercoledì, Maggio 8, 2024
USD, World Health Organization, Pregnancy, Infertility, OTC, Health, Helm, Research, STI, DNA, Chlamydia, Privacy, Infection, Gonorrhea, Chronic pain, Birth control

Current tests for these most commonly reported notifiable infections in the United States require in-clinic office visits and results can take days.

Key Points: 
  • Current tests for these most commonly reported notifiable infections in the United States require in-clinic office visits and results can take days.
  • Testmate Health's simple urine test is designed to provide lab-quality results at home in under 30 minutes.
  • Her research at the World Health Organization emphasized the absence of cheap and accurate STI tests, leading her to develop Testmate's revolutionary urine-based DNA platform detection technology.
  • Testmate's proprietary STI self-test will be the first to make at-home STI testing as ubiquitous as an at-home pregnancy test.

MISTR, Known for its Free Online PrEP and Long-Term HIV Care, is Now Prescribing DoxyPEP

Retrieved on: 
Martedì, Aprile 16, 2024
Telemedicine, Virtual Medicine, Other Health, Pharmaceutical, Other Consumer, General Health, Philanthropy, Women, Infectious Diseases, Men, LGBTQ+, Other Philanthropy, AIDS, Lifestyle, Consumer, Health, Telehealth, Syphilis, NIH, Post-exposure prophylaxis, STI, ART, Patient, Chlamydia, Doxycycline, HIV, Gonorrhea, Pharmaceutical industry

MISTR, the largest telemedicine provider offering free online PrEP and long-term HIV care in all 50 states, D.C., and Puerto Rico, is now prescribing Doxycycline Post-Exposure Prophylaxis (DoxyPEP), an antibiotic that reduces bacterial STIs, including gonorrhea, chlamydia, and syphilis.

Key Points: 
  • MISTR, the largest telemedicine provider offering free online PrEP and long-term HIV care in all 50 states, D.C., and Puerto Rico, is now prescribing Doxycycline Post-Exposure Prophylaxis (DoxyPEP), an antibiotic that reduces bacterial STIs, including gonorrhea, chlamydia, and syphilis.
  • Beginning today, patients can now use MISTR’s seamless telehealth platform to receive DoxyPEP online for free.
  • “I’m proud that MISTR is democratizing access to PrEP, HIV Care, and now DoxyPEP.”
    DoxyPEP has already shown promising results in reducing the rates of certain STIs.
  • Now MISTR patients can receive DoxyPEP, in addition to their PrEP or HIV care medications.

Coachella Concerned That People Have Sex, Says AHF

Retrieved on: 
Giovedì, Marzo 28, 2024
Entertainment, AIDS, Health, Infectious Diseases, Music, Events, Concerts, AIDS Healthcare Foundation, STD, Condom, Syphilis, URL, Sand, Coachella (festival), United, STI, Gonorrhea, CDC, Chlamydia, AHF, Multimedia, Advertising, Pharmaceutical industry

(Photo: Business Wire)

Key Points: 
  • (Photo: Business Wire)
    The Coachella-themed billboard went up Tuesday, March 26, 2024 and will remain up throughout April as Coachella spans two weekends: April 12-14 and April 19-21.
  • Do they really not know how people spend their time during festival weekends?” said Michael Weinstein, AHF president and cofounder.
  • California ranks 22 in reported cases of chlamydia, 18th in reported cases of gonorrhea, and 19th in cases of syphilis.
  • To learn more about AHF, visit us online at AIDShealth.org , find us on Facebook , follow us on Instagram , Twitter , and TikTok , and subscribe to our AHFter Hours podcast.

Government of Canada supports community-based projects addressing HIV, Hepatitis C, and other sexually transmitted and blood-borne infections

Retrieved on: 
Venerdì, Febbraio 23, 2024
Parliament, HIV/AIDS, Infection, Syphilis, Investment, Quality of life, Harm reduction, Government, Hepatitis, Address, CAF, Risk, Public Health Agency, PHAC, Stigma, HRF, Chlamydia, Knowledge, Hepatitis C, Gonorrhea, Mental health, HIV, Public

However, these infections remain a significant public health concern in Canada, especially among Indigenous, 2SLGBTQ+, and other equity-deserving communities.

Key Points: 
  • However, these infections remain a significant public health concern in Canada, especially among Indigenous, 2SLGBTQ+, and other equity-deserving communities.
  • Today's funding includes more than $12 million through the CAF, which will support 15 community-based interventions to address HIV, hepatitis C and other STBBI.
  • In 2022, the Government of Canada invested $106.4 million to help address STBBI across Canada.
  • Through the HIV and Hepatitis C Community Action Fund, the Public Health Agency of Canada (PHAC) invests $26.4 million annually to support time-limited projects (up to 5 years) across Canada to address HIV, hepatitis C and other sexually transmitted infections (e.g., chlamydia, gonorrhea, syphilis).

binx health Enters into National Distribution Agreement with Cardinal Health to Increase Access to the CLIA-waived, FDA-cleared binx io

Retrieved on: 
Lunedì, Febbraio 12, 2024
Cardinal, Hospital, POC, FDA, Infection, Female, Pharmacy, Cardinal Health, Emergency, World Congress, Patient, CLIA, Diagnosis, Male, Gonorrhea, Chlamydia, STI, Medical imaging

Collaborating with Cardinal Health provides binx health with additional access to the acute clinical care settings via its vast sales network in the market.

Key Points: 
  • Collaborating with Cardinal Health provides binx health with additional access to the acute clinical care settings via its vast sales network in the market.
  • We are proud that we have earned their trust in binx and the binx io," said Jeffrey Luber, binx health’s Chief Executive Officer.
  • With this distribution collaboration, together binx health and Cardinal Health teams will help improve access to the treatment of CT/NG.
  • For more information about the binx io, visit mybinxhealth.com/binx-io or contact your Cardinal Health representative.

binx health Expands Nationwide Distribution of the binx io Molecular Point-of-Care Platform

Retrieved on: 
Lunedì, Novembre 27, 2023
STI, Male, FDA, POC, Gonorrhea, Thermo Fisher Scientific, CLIA, World Congress, Chlamydia, Diagnosis, Female

BOSTON, Nov. 27, 2023 (GLOBE NEWSWIRE) -- binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, today announced it has entered into a non-exclusive national distribution agreement with Fisher Healthcare, a part of Thermo Fisher Scientific, to expand the rollout of the CLIA-waived, FDA-cleared binx io, which will increase access to care and improve the timely diagnosis of chlamydia (CT) and gonorrhea (NG).

Key Points: 
  • BOSTON, Nov. 27, 2023 (GLOBE NEWSWIRE) -- binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, today announced it has entered into a non-exclusive national distribution agreement with Fisher Healthcare, a part of Thermo Fisher Scientific, to expand the rollout of the CLIA-waived, FDA-cleared binx io, which will increase access to care and improve the timely diagnosis of chlamydia (CT) and gonorrhea (NG).
  • The binx io is the only molecular point-of-care (POC) platform proven to detect CT and NG in both male and female patient samples that provides central lab performance in about thirty minutes.
  • Data presented at the STI & HIV 2023 World Congress in Chicago demonstrated that hands-on-time for the POC binx io is statistically the same as the hands-on-time for collecting a CT/NG sample for send out to a central lab.
  • CT/NG results from the binx io were available days before test results were available from the central lab CT/NG test [1].

LetsGetChecked Receives U.S. Food and Drug Administration (FDA) De Novo Authorization for At-Home Chlamydia and Gonorrhea Testing System

Retrieved on: 
Giovedì, Novembre 16, 2023
Biotechnology, Medical Supplies, General Health, Health, FDA, Infectious Diseases, Health Technology, Other Health, Classification, Chlamydia, STI, De novo, Food, Gold, Doctor of Philosophy, Gonorrhea, HIV, CDC, Vertically transmitted infection, News, Medical device

LetsGetChecked, a global healthcare solutions company, announced today that the U.S. Food and Drug Administration (FDA) has granted the company’s De Novo classification request for its Simple 2 at-home collection system.

Key Points: 
  • LetsGetChecked, a global healthcare solutions company, announced today that the U.S. Food and Drug Administration (FDA) has granted the company’s De Novo classification request for its Simple 2 at-home collection system.
  • FDA’s De Novo authorization makes LetsGetChecked’s testing system for chlamydia and gonorrhea the first-ever FDA-authorized home sample collection system with retail and online access to the collection kit.
  • The CDC reports that in 2021 there were an estimated 1.6 million cases of chlamydia and more than 700,000 cases of gonorrhea.
  • “We are honored to receive this landmark De Novo classification and authorization from FDA for our chlamydia and gonorrhea testing system, which demonstrates the value of our robust end-to-end at-home care system,” said Peter Foley, Founder and CEO of LetsGetChecked.

World Emerging Infectious Disease Diagnostics Market Research Report 2023: Respiratory Infections Take Center Stage in Infectious Disease Diagnostics Post-COVID-19 - ResearchAndMarkets.com

Retrieved on: 
Mercoledì, Ottobre 25, 2023
Infectious Diseases, Health, Other Health, RSV, Region, Infection, Chlamydia, Respiratory syncytial virus, SARS-CoV-2, Government, Urinary tract infection, Influenza, CRISPR, Ebola, PCR, Developed country, Virus, Virulence, POCT, Whole genome sequencing, Growth, Point-of-care testing, STI, NGS, Streptococcus, RT-LAMP, COVID-19, Mumps, Hospital, Gonorrhea, WGS, Polymerase chain reaction, Bacteria, Rubella, Hepatitis, Syphilis, Tuberculosis, Diagnosis, Gastroenteritis, Zika fever, POC, Pharmaceutical industry, Vaccine, Medical imaging, Medical device

The emergence of the COVID-19 pandemic has had a profound and far-reaching impact on infectious disease diagnostics worldwide.

Key Points: 
  • The emergence of the COVID-19 pandemic has had a profound and far-reaching impact on infectious disease diagnostics worldwide.
  • North America, encompassing both the United States and Canada, currently holds the largest share in the global emerging infectious disease diagnostics market.
  • Some of the common bacterial infections include respiratory infections such as tuberculosis and streptococcal infections and sexually transmitted infections (STIs) such as chlamydia, gonorrhea, and syphilis.
  • Hospitals and clinics play a critical role in the field of infectious disease diagnostics, serving as important centers for patient evaluation and testing.

PHASE Scientific Americas Announces INDICAID Health™ At-Home Test Kits and Digital Health Platform

Retrieved on: 
Mercoledì, Ottobre 25, 2023
Seniors, General Health, Health, Medical Devices, Convenience Store, Online Retail, Consumer, Retail, Science, Korea Disease Control and Prevention Agency, Chlamydia, CDC, STI, Gonorrhea, Vaginitis, COVID-19, Bacterial vaginosis, Pharmacy, Patient, Empathy, BV, Infection, Medical device, Trichomoniasis, COVID, Candidiasis

PHASE Scientific Americas (PHASE Scientific), a fast-growing, global biomedical company developing innovative solutions to revolutionize healthcare diagnostics, announces INDICAID health™, its new line of at-home health tests and digital health experiences.

Key Points: 
  • PHASE Scientific Americas (PHASE Scientific), a fast-growing, global biomedical company developing innovative solutions to revolutionize healthcare diagnostics, announces INDICAID health™, its new line of at-home health tests and digital health experiences.
  • INDICAID health™ was created to help patients get back to better health faster and with less hassle.
  • “INDICAID health™ supports PHASE Scientific’s mission of shaping the future of at-home, personal diagnostics with people-first, science-based innovations,” said Felix Chao, General Manager of PHASE Scientific Americas.
  • The INDICAID health™ Sexual Health 2 test checks for the top two common STIs: Chlamydia and Gonorrhea.